Biofrontera AG (NASDAQ:BFRA) headquartered in Leverkusen, will host a conference call for the investment community to discuss the 3Q20 earnings result on 12th November 2020 at 10:00 AM Eastern Time.
The financial results for the quarter are released after the U.S. market close on Wednesday 11th November 2020
Those interested in listening to the conference call live via the Internet can visit www.biofrontera.com
Individuals interested in participating in the audio call may dial the listen only number(s) +1 8774230830 (United States), with passcode : 17972359
Earnings Expectation
Biofrontera AG is set to announce third quarter earning results on Wednesday 11th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BFRA to report 3Q20 loss of $ 0.34 per share. For the full year, analysts anticipate top line of $ 34.80 million, while looking forward to loss of $ 0.82 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 5.49 million ~ $ 5.73 million
Full Year 2020 topline are forecasted in a range of$ 38.42 million ~ $ 42.94 million
Click Here For More Historical Outlooks Of Biofrontera AG
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products.
